首页> 外国专利> Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents (hypocholesterolemic agents useful as hypocholesterolemic agents)

Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents (hypocholesterolemic agents useful as hypocholesterolemic agents)

机译:用作降胆固醇药的螺环烷基取代的氮杂环丁酮(用作降胆固醇药的降胆固醇药)

摘要

The present invention relates to the use of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof, an anticholinergic pharmaceutical composition, a use of the compound as a hypocholesterolemic agent, a method for producing the compound and atherosclerosis To the use of the combination of the compound and a cholesterol biosynthesis inhibitor.;Wherein ROnesilver;And R2And R3Is independently-CH2-,-CH (lower alkyl)-,-C (di-lower alkyl)-,-CH =3Together with-CH = CH-or-CH = C (lower alkyl)-group, u and V are independently 0, 1, 2 or 3,2Is-CH = CH-or-C (lower alkyl) = CH-, then v is 1 and R3Is-CH = CH-or-C (lower alkyl) = CH-, when u is 1 and v is 2 or 3, all R2May be the same or different, and when u is 2 or 3, all R3May be the same or different, and R4(CH2)mC (O)-, wherein m is 0, 1, 2, 3, 4 or 5, B-(CH2)q-(wherein q is 0, 1, 2, 3, 4, 5 or 6), B-(CH2)e-Z-(CH2)r-, wherein Z is-O-,-C (O)-, phenylene,-N (R8)-or-S (O)0-2E is 0, 1, 2, 3, 4 or 5 and r is 0, 1, 2, 3, 4 or 5, provided that the sum of e and r is 0, 1, 2, 5, with the proviso that the sum of e and r is 0, 1, 2, 3, 4, 5 or 6, B-(C2-C6Alkenylene)-, B-(C4-C6Alkadienylene)-, B-(CH2)t-Z-(C2-C6Alkenylene)-, wherein Z is as defined above and t is 0, 1, 2, or 3, provided that the sum of t and the number of carbon atoms of the alkenylene chain is 2, 3, 4, 5 or 6, B-(CH2)t-V-(CH2)g-wherein V is C3-C6F is 1, 2, 3, 4 or 5 and g is 0, 1, 2, 3, 4 or 5, provided that the sum of f and g is 0, 1, 2, 3, 4, 5 or 6), B-(CH2)t-V-(C2-C6Alkenylene) or B '-(C2-C6Alkenylene)-V-(CH2)t-, wherein V and t are as defined above, provided that the sum of t and the number of carbon atoms of the alkenylene chain is 2, 3, 4, 5 or 6, B-(CH2)a-Z-(CH2)b-V-(CH2)dB and d are independently 0, 1, 2, 3, 4, 5 or 6, provided that the sum of a, b and d is 0, 1, 2 , 3, 4, 5 or 6), T-(CH2)s-wherein T is cycloalkyl of 3 to 6 carbon atoms and s is 0, 1, 2, 3, 4, 5 or 6, or ROneAnd R4Group together;Wherein B is indanyl, indenyl, naphthyl, tetrahydronaphthyl, heteroaryl or W-substituted heteroaryl wherein the heteroaryl is pyrrolyl, pyridinyl, pyrimidinyl, pyrazinyl, Thiazolyl, pyrazolyl, thienyl, oxazolyl and furanyl, in the case of nitrogen-containing heteroaryl it is an N-oxide thereof) or;W is a substituent on a ring carbon atom and is independently selected from the group consisting of lower alkyl, hydroxy lower alkyl, lower alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxycarbonylalkoxy, (lower alkoxyimino) Lower alkyl lower alkanedioyl, allyloxy,-CF3-, OCF3, Benzyl, R7-benzyl, benzyloxy, R7-Benzyloxy, phenoxy, R7-phenoxy, dioxolanyl, NO2,-N (R8) (R9), N (R8) (R9)-lower alkylene-, N (R8) (R9)-lower alkylenedioxy-, OH, halogeno,-CN,-N3,-NHC (O) OR10,-NHC (O) R10M R11O2SNH-, (R11O2S)2N-,-S (O)2NH2,-S (O)0-2R8, Tert-butyldimethylsilyloxymethyl,-C (O) R12,-COOR19,-CON (R8) (R9),-CH = CHC (O) R12,-lower alkylene-C (O) R12, R10C (O) (lower alkylenedioxy)-, N (R8) (R9) C (O) (lower alkylenedioxy)-and-;Lower alkyl, lower alkoxy,-C (O) OR RTI ID = 0.0 10,-C (O) R 0, OH, N (R8) (R9)-lower alkylene-, N (R8) (R9)-lower alkyleneoxy-,-S (O)2NH2And 2-(trimethylsilyl)-ethoxymethyl, wherein R RTI ID = 0.0 7Is independently selected from the group consisting of lower alkyl, lower alkoxy,-COOH, NO2,-N (R8) (R9), OH or halogeno, R 3 8And R9Is independently H or lower alkyl, R10Is lower alkyl, phenyl, R7-phenyl, benzyl or R7-benzyl, R11Is OH, lower alkyl, phenyl, benzyl, R7-phenyl or R7-benzyl, R12Is H, OH, alkoxy, phenoxy, benzyloxy,;-N (R8) (R9), Lower alkyl, phenyl or R7-phenyl, R13Is-O-,-CH2-,-NH-,-N (lower alkyl)-or-NC (O) R19And R15, R16And R17Are independently selected from the group consisting of the groups defined for H and W, or R15Is hydrogen, R16And R17Together with the adjacent carbon atoms form a dioxolanyl ring, R19Is H, lower alkyl, phenyl or lower alkyl, and R20And R21Are independently phenyl, W-substituted phenyl, naphthyl, W-substituted naphthyl, indanyl, indenyl, tetrahydronaphthyl, benzodioxolyl, heteroaryl, W-substituted heteroaryl, benzo fused heteroaryl , W-substituted benzo-fused heteroaryl, and cyclopropyl, wherein the heteroaryl is as defined above.
机译:本发明涉及通式(I)的化合物或其药学上可接受的盐的用途,抗胆碱能药物组合物,该化合物作为降血脂药的用途,该化合物的制备方法和动脉粥样硬化。化合物与胆固醇生物合成抑制剂的组合的通式;其中R One 银;和R 2 和R 3 分别是-CH < Sub> 2 -,-CH(低级烷基)-,-C(二低级烷基)-,-CH = 3 与-CH = CH-或-CH = C (低级烷基)-基团,u和V独立地为0、1、2或3, 2 Is-CH = CH-或-C(低级烷基)= CH-,则v为1和R 3 Is-CH = CH-或-C(低级烷基)= CH-,当u为1且v为2或3时,所有R 2 可能是相同或不同,并且当u为2或3时,所有R 3 可以相同或不同,并且R 4 (CH 2 m C(O)-,其中m为0、1、2、3、4或5,B-(CH 2 q -(wh erein q是0、1、2、3、4、5或6),B-(CH 2 e -Z-(CH 2 r -,其中Z为-O-,-C(O)-,亚苯基,-N(R 8 )-或-S(O)< Sub> 0-2 E为0、1、2、3、4或5,并且r为0、1、2、3、4或5,前提是e和r的总和为0、1, 2、5,e和r之和为0、1、2、3、4、5或6,前提是B-(C 2 -C 6 亚烯基)-,B-(C 4 -C 6 亚烷基二烯基)-,B-(CH 2 t -Z-(C 2 -C 6 亚烯基)-,其中Z如上定义,t为0、1、2或3,条件是t和亚烯基链的碳原子数之和为2、3、4、5或6,B-(CH 2 t -V-(CH 2 g -其中V是C 3 -C 6 F是1,2,3,4或5和g为0、1、2、3、4或5,前提是f和g的总和为0、1、2、3、4、5或6),B-(CH 2 t -V-(C 2 -C 6 亚烯基)或B'-(C 2 -C 6 亚链烯基)-V-( CH 2 t -,其中V和t如上定义,条件是t与亚烯基链的碳原子总数之和为2、3, 4,5或6,B-(CH 2 a -Z-(CH 2 b - V-(CH 2 d B和d分别为0、1、2、3、4、5或6,前提是a,b和d之和是0、1、2、3、4、5或6),T-(CH 2 s -其中T是3至6个碳原子的环烷基分别为0、1、2、3、4、5或6或R One 和R 4 基团;其中B为茚满基,茚基,萘基,四氢萘基,杂芳基或W-取代的杂芳基,其中杂芳基为吡咯基,吡啶基,嘧啶基,吡嗪基,噻唑基,吡唑基,噻吩基,恶唑基和呋喃基,在含氮杂芳基的情况下,其为N-氧化物);或; W为在其上的取代基环碳原子,并且独立地选自低级烷基,羟基低级烷基,低级烷氧基,烷氧基烷基,烷氧基烷氧基,烷氧基羰基烷氧基,(低级烷氧基亚氨基)低级烷基低级烷二羰基,烯丙氧基,-CF 3 -,OCF 3 ,苄基,R 7 -苄基,苄氧基,R 7-苄氧基,苯氧基,R 7 -苯氧基,二氧戊环基,NO 2 ,-N(R 8 < / Sub>)(R 9 ),N(R 8 )(R 9 )-低级亚烷基-,N(R 8 )(R 9 )-低级亚烷基二氧基-,OH,卤代,-CN,-N 3 ,-NHC(O)OR 10 ,-NHC(O)R 10 MR 11 O 2 SNH-,(R 11 O 2 S) 2 N-,-S(O) 2 NH 2 ,-S(O) 0-2 R 8 ,叔丁基二甲基甲硅烷基氧甲基,-C(O)R 12 ,-COOR 19 , -CON(R 8 )(R 9 ),-CH = CHC(O)R 12 ,-低级亚烷基-C(O) R 12 ,R 10 C(O)(低级亚烷基二氧基)-,N(R 8 )(R 9 )C(O)(低级亚烷基二氧基)-和-;低级烷基,低级烷氧基-C(O)OR 10 ,-C(O)R Sub > 0 , OH,N(R 8 )(R 9 )-低级亚烷基-,N(R 8 )(R 9 )-低级亚烷基氧基-,-S(O) 2 NH 2 和2-(三甲基甲硅烷基)-乙氧基甲基,其中R 7 独立地选自低级烷基,低级烷氧基,-COOH,NO 2 ,-N(R 8 )(R 9 ),OH或卤代,R <3> 8 和R 9 独立地为H或低级烷基,R 10 为低级烷基,苯基,R 7 -苯基,苄基或R 7 -苄基,R 11 为OH,低级烷基,苯基,苄基, R 7 -苯基或R 7 -苄基,R 12 为H,OH,烷氧基,苯氧基,苄氧基;;-N(R < Sub> 8 )(R 9 ),低级烷基,苯基或R 7 -苯基,R 13 Is-O- ,-CH 2 -,-NH-,-N(低级烷基)-或-NC(O)R 19 和R 15 , R 16 和R 17 分别选自H和W定义的组或R 15 是氢,R 16 和R 17 与相邻的碳原子一起形成一个二氧戊环,R 19 < / Sub>是H,低级烷基,苯基或低级烷基,并且R 20 和R 21 分别是苯基,W取代的苯基,萘基,W取代的萘基,茚满基,茚基,四氢萘基,苯并二恶唑基,杂芳基,W-取代的杂芳基,苯并稠合的杂芳基,W-取代的苯并稠合的杂芳基和环丙基,其中杂芳基如上所定义。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号